Xin Lang Cai Jing·2025-09-08 03:32Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, primarily joint prosthetics and spinal implants [2] - As of June 30, the company reported a revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, with a year-on-year increase of 44.85% [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed in the last three years [3] Group 2 - As of September 5, the financing balance of the company was 33.27 million yuan, accounting for 0.49% of its market capitalization, which is above the 60th percentile level over the past year [1] - On September 5, the company had a net financing purchase of 1.12 million yuan, with a financing buy-in of 5.93 million yuan and a repayment of 4.81 million yuan [1] - The company had no short selling activity on September 5, with a short selling balance of 0 shares, indicating a high level of investor confidence [1] Group 3 - The number of shareholders as of June 30 was 5,920, a decrease of 17.57% from the previous period, while the average circulating shares per person increased by 341.41% to 48,836 shares [2] - Among the top ten circulating shareholders, Ping An Low Carbon Economy Mixed A Fund increased its holdings by 2.77 million shares, while Southern Medical Health Flexible Allocation Mixed A Fund entered the list as a new shareholder with 1.60 million shares [3] - The company exports its products to various regions including Asia, South America, Africa, Oceania, and Europe [2]